Savara (SVRA) logo

Savara (SVRA) stock

Pre-market
$4.78
+3.02%

Respiratory medicines, worth $1.0BSmall-cap biotech

Close $4.64 -1.69%

Quality Score
-4
Poor
In its industry
#71of 89
Checks firing
1of 14
Choppy
From 52-week high
-33.8%
under its best in a year

SVRA's Quality Score was unchanged on Fri, Nov 13, at -4.

Follow SVRA's trial news. Pro members can get an alert when Savara files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SVRA files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextNov 22, 2026 · In 6 days…three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026…FDA decision date · SEC filing · Nov 9
Cash$130M, about 4 quarters at the last year's spendingOn Sep 30

Why SVRA beats the market

Up 307% over five years while the S&P 500 rose 73%; up 9% in the past year.

  • Its filed figures weakened while the shares beat the market.

No filing or news in our sources explains it.

Sources: Price history, Nov 13, 2026; Quarterly reports, Sep 30, 2026

The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on SVRA

Key facts on SVRA
Holding it backA $153M loss wider than $116M a year earlier
Latest filing10-Q, Nov 9 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026
1 more reason behind SVRA's -4, free with an account →3 more reasons behind SVRA's -4, for Pro members.
Cash$130M, about 4 quarters at the last year's spendingOn Sep 30

SVRA catalysts

Coming up

After its last 3 reports it closed +1.9% on average, higher 2 of 3 times.

What's next for SVRA, and how long its cash lasts

Next step the company has named

Nov 22In 6 days…during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.FDA decision date · SEC filing · Nov 9

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

More on Molgramostim's FDA date

Lead program
Molgramostim · Autoimmune Pulmonary Alveolar Proteinosis · under FDA review
Its trial
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Phase 3 · Recruiting · 5 people · main data estimated Jun 2027 · NCT06431776

1 more trial, 21 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 4 quarters

$130M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 9, 2024)
  • At-the-market share sales program (S-3, filed May 9, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO David L Lowrance sold 394,528 shares on Jun 22.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Matthew Pauls’s 4 filings and quotes.

Get an alert before SVRA's FDA date

A free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

Why SVRA scores -4

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

  • +1Chart checks 1 of 14 firing right now, one point each
  • −1Long-term trend below a falling 200-⁠day average
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on SVRA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 5:03 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when SVRA's Quality Score turns up

A free account. No card.Pro, 7 days free with a card.

How SVRA ranks in Pharma

SVRA is #71 of 89 by Quality Score.

How SVRA ranks in Pharma
RankStockQuality Score
71Savara (SVRA) logoSVRASavara-4

Net income over four quarters: SVRA -$153M, INO -$71.1M, AGIO -$373M.

More in Pharma

When does SVRA report earnings, and what happens after?

Expected to report Fri Mar 12, after the close (in 116 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+3.4%-1.3%+3.7%
Nov 12Mar 13May 12
ReportedGapReaction5
days
May 12, 2026After close-5.1%+3.7%-7.1%
Mar 13, 2026Before open0.0%-1.3%-3.0%
Nov 12, 2025After close+0.5%+3.4%+11.7%

SVRA closed higher after 2 of its last 3 reports.

SVRA has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on SVRA, and all 14 on every stock.Get in free →

SVRA RSI on Nov 13: 45.9, below its 50-day and 200-day averages

Not scored

RSI 45.9, MACD above signal, below both averages. Not scored.

The deep dive on SVRA

8 more findings on SVRA, each with its source, for Pro members.

SVRA share count over time

17% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of SVRA outstanding, as filed
Shares
outstanding
As
of
220.6MNov 9, 2026
205.5MAug 11, 2026
204.9MMay 12, 2026
204.7MMar 13, 2026
Offerings, shelves, and splits of SVRA, from its filings
From its
filings
Filed
Raised $100M in a sale of shares, about 10% of its market valueOct 30, 2025
Priced a sale of sharesJun 28, 2024
Registered shares for a later sale (S-3)May 9, 2024

SVRA insider trades

One insider sold $2.2M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellDavid L. Lowrance$2.2MChief Financial Officerat $5.68 on Jun 22, filed Jun 22

SVRA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

5 more officers and directors file at SVRA.

See insider trades by person

Which ETFs hold SVRA?

In ETFs: SVRA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

70 employeesAustin, TXsavarapharma.com

What Savara says it competes with

“The pharmaceutical industry is highly competitive and subject to continuous technological change.”

From its annual report, SEC filing · Mar 10, 2021

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on SVRA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn SVRA's score around: 8 things
  • 4 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayJun 22David L. Lowrance sold SVRA$2.2M at $5.68, filed Jun 22

Alerts are optional.

See SVRA's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: SVRA's Quality Score is -4 (Poor), #71 of 89 in Pharma. Insiders sold $2.2M in the last 6 months (Form 4).

What does SVRA's Quality Score say?

SVRA scores -4 today, which Breakaway calls Poor. It is #71 of 89 in Pharma by Quality Score, with 1 of 14 chart checks firing. Up 307% over five years while the S&P 500 rose 73%; up 9% in the past year. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SVRA's Quality Score?

SVRA scores -4 today, which Breakaway calls Poor (below zero). That is #71 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SVRA's -4.

Are insiders buying SVRA?

One insider sold $2.2M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is David L. Lowrance, Chief Financial Officer, who sold $2.2M on Jun 22.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Savara: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.